Literature DB >> 6756362

Diacetyl derivative of nadolol. I. Ocular pharmacology and short-term ocular hypotensive effect in glaucomatous eyes.

E Duzman, C C Chen, J Anderson, M Blumenthal, H Twizer.   

Abstract

On topical application to rabbit eyes, the diacetate ester of nadolol was more easily absorbed into ocular tissue than nadolol and was enzymatically hydrolyzed to nadolol within the eye. In a 24-hour clinical study, the ocular hypotensive activities of 0.5% diacetyl nadolol, 2% diacetyl nadolol, 2% nadolol, and 0.5% timolol maleate in subjects with open-angle glaucoma or ocular hypertension were compared. Both concentrations of diacetyl nadolol significantly reduced intraocular pressure during the first six hours. Two percent diacetyl nadolol was as effective as 0.5% timolol maleate during the first eight hours. During the remainder of the testing period, timolol showed greater IOP control. Two percent diacetyl nadolol and 2% nadolol showed similar ocular hypotensive effects both in magnitude and duration in this short-term study.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6756362     DOI: 10.1001/archopht.1982.01030040896005

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

Review 1.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Synthesis, physicochemical properties, and cytotoxicity of a series of 5'-ester prodrugs of 5-iodo-2'-deoxyuridine.

Authors:  M M Narurkar; A K Mitra
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

3.  A comparison of the effects of oral nadolol and topical timolol on intraocular pressure, blood pressure, and heart rate.

Authors:  G R Duff; A H Watt; P A Graham
Journal:  Br J Ophthalmol       Date:  1987-09       Impact factor: 4.638

4.  Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes.

Authors:  E Duzman; N Rosen; M Lazar
Journal:  Br J Ophthalmol       Date:  1983-10       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.